Michael Burgess actually said...

"It is vital that the Food and Drug Administration routinely incorporate the patient perspective in its decisionmaking process."

"I want to thank the FDA and the industry and patient advocates and providers and other stakeholders for their work on this agreement."

"This is a good thing because it will get safe and effective products to doctors and to patients faster."

"Reauthorizing the Medical Device User Fee Agreements and the user fee programs we have previously discussed would increase efficiency at FDA."